Neurocrine Biosciences, Inc. (NBIX) Q1 2011 Earnings Results

Neurocrine Biosciences Misses on EPS, Stock Up 0.39%

This earnings report indicates that Neurocrine Biosciences faced challenges in meeting EPS expectations, but the stock reacted positively, gaining 0.39%. Investors may be encouraged by management's focus on future developments and the potential of their product pipeline, despite the EPS miss.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.05	N/A	-5.66%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management remains focused on their strategic initiatives. They acknowledged the EPS miss but emphasized long-term growth prospects.

Management highlighted ongoing development efforts and future potential.

They expressed confidence in their pipeline despite the EPS miss.

Neurocrine Biosciences Misses on EPS, Stock Up 0.39%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS, Stock Up 0.39%

Key numbers

Management commentary